HPV HANDBOOK - Zervita

More documents

Recommendations

Info

HPV TESTING AS A SCREENING TEST: THE CASE FORReferences1. Jacobs MV, Walboomers JM, Snijders PJ et al. Distribution of 37mucosotropic HPV types in women with cytologically normal cervicalsmears: the age-related patterns for high-risk and low-risk types. Int JCancer 2000;87:221–72. Ho GY, Bierman R, Beardsley L et al. Natural history of cervicovaginalpapillomavirus infection in young women. N Engl J Med 1998;338:423–83. Koutsky LA, Holmes KK, Critchlow CW et al. A cohort study of the risk ofcervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirusinfection. N Engl J Med 1992;327:1272–84. Woodman CB, Collins S, Winter H et al. Natural history of cervical humanpapillomavirus infection in young women: a longitudinal cohort study.Lancet 2001;357:1831–65. Bulk S, Visser O, Rozendaal L et al. Incidence and survival rate of womenwith cervical cancer in the Greater Amsterdam area. Br J Cancer2003;89:834–96. Zielinski GD, Snijders PJ, Rozendaal L et al. High-risk HPV testing inwomen with borderline and mild dyskaryosis: long-term follow-up data andclinical relevance. J Pathol 2001;195:300–67. Clavel C, Masure M, Bory JP et al. Human papillomavirus testing in primaryscreening for the detection of high-grade cervical lesions: a study of 7932women. Br J Cancer 2001;84:1616–238. Nobbenhuis MA, Meijer CJ, van den Brule AJ et al. Addition of high-riskHPV testing improves the current guidelines on follow-up after treatment forcervical intraepithelial neoplasia. Br J Cancer 2001;84:796–8019. Rozendaal L, Westerga J, van der Linden JC et al. PCR based high risk HPVtesting is superior to neural network based screening for predicting incidentCIN III in women with normal cytology and borderline changes. J Clin Pathol2000;53:606–1110. Wallin KL, Wiklund F, Angstrom T et al. Type-specific persistence of humanpapillomavirus DNA before the development of invasive cervical cancer. NEngl J Med 1999;341:1633–811. van Duin M, Snijders PJ, Schrijnemakers HF et al. Human papillomavirus 16load in normal and abnormal cervical scrapes: an indicator of CIN II/III andviral clearance. Int J Cancer 2002;98:590–533
3: HPV AND CERVICAL CANCER: PUBLIC HEALTH PERSPECTIVES12. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of humanpapillomavirus testing: relationship between analytical and clinicalsensitivity. J Pathol 2003;201:1–613. Josefsson AM, Magnusson PK, Ylitalo N et al. Viral load of humanpapilloma virus 16 as a determinant for development of cervical carcinomain situ: a nested case-control study. Lancet 2000;355:2189–9314. Lorincz AT, Richart RM. Human papillomavirus DNA testing as an adjunctto cytology in cervical screening programs. Arch Pathol Lab Med2003;127:959–6815. Zielinski GD, Snijders PJ, Rozendaal L et al. HPV presence precedesabnormal cytology in women developing cervical cancer and signals falsenegative smears. Br J Cancer 2001;85:398–40416. Jain S, Tseng CJ, Horng SG et al. Negative predictive value of humanpapillomavirus test following conization of the cervix uteri. Gynecol Oncol2001;82:177–8017. Kucera E, Sliutz G, Czerwenka K et al. Is high-risk human papillomavirusinfection associated with cervical intraepithelial neoplasia eliminated afterconization by large-loop excision of the transformation zone? Eur J Obstet,Gynecol Reprod Biol 2001;100:72–0618. Lin CT, Tseng CJ, Lai CH et al. Value of human papillomavirusdeoxyribonucleic acid testing after conization in the prediction of residualdisease in the subsequent hysterectomy specimen. Am J Obstet Gynecol2001;184:940–519. Kanamori Y, Kigawa J, Minagawa Y et al. Residual disease and presence ofhuman papillomavirus after conization. Oncology 1998;55:517–2020. Nobbenhuis MA, Meijer CJ, van den Brule AJ et al. Addition of high-riskHPV testing improves the current guidelines on follow-up after treatment forcervical intraepithelial neoplasia. Br J Cancer 2001;84:796–80121. Zielinski GD, Snijders PJ, Rozendaal L et al. The presence of high-risk HPVcombined with specific p53 and p16INK4a expression patterns points tohigh-risk HPV as the main causative agent for adenocarcinoma in situ andadenocarcinoma of the cervix. J Pathol 2003;201:535–4334
Page 4 and 5: THE HEALTH PROFESSIONAL’SHPV HAND
Page 6: ContentsList of contributors 7Intro
Page 10: Introduction to the HPV Handbook se
Page 13 and 14: 3: HPV AND CERVICAL CANCER: PUBLIC
Page 26 and 27: 2. HPV testing as a screeningtest:
Page 28 and 29: HPV TESTING AS A SCREENING TEST: TH
Page 36 and 37: 3. HPV testing as a screeningtest:
Page 44: HPV TESTING AS A SCREENING TEST: TH
Page 66 and 67: THE POTENTIAL PUBLIC HEALTH IMPACT
Page 80 and 81: Indexadenocarcinoma,detection by HP
Page 82 and 83: INDEXuse in ASCUS 53use to confirm

HPV HANDBOOK - Zervita

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?